[Fully possible to reduce the costs of hypertension treatment].
Wettermark
Björn
B
Läkemedelscentrum, Stockholms läns landsting.
Angman
Anna
A
Hjemdahl
Paul
P
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000191:economics; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000191:economics; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000191:economics; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D004232:Diuretics / Q000008:administration & dosage / Q000191:economics; D016527:Drug Costs; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000191:economics*; D017063:Outcome Assessment, Health Care; D010818:Practice Patterns, Physicians' / Q000191:economics; D013548:Sweden
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics